Abstract: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.

Abstract: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand.

Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form.

Abstract: Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5. Also disclosed is a kit for detecting cancer or monitoring cancer progression.

Abstract: Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CXCL13 and/or the chemokine receptor CXCR5. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CXCL13 and/or the chemokine receptor CXCR5.

Abstract: Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9.

Abstract: Methods for detecting cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprise CCL25 or CCR9 or both CCL25 and CCR9.

Abstract: Methods for detecting cancer or monitoring cancer progression in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL16 or CXCR6 or both CXCL16 and CXCR6. Also disclosed is a kit for detecting cancer or monitoring cancer progression.

Abstract: Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CXCL16 and/or the chemokine receptor CXCR6. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CXCL16 and/or the chemokine receptor CXCR6.

Abstract: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.

Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

Abstract: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications.

Abstract: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications.

Abstract: This disclosure describes tools for navigating within applications, and in particular business applications. For example, a menu system may incorporate a notification system, such that notifications of events received at a business application are displayed within the context of the menu system. The user can be allowed to select an event from the menu system, allowing the user to quickly navigate to a context, within the application, corresponding to the event.

Abstract: Milled nanoparticles comprising a biolgically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications

Abstract: A process is provided for inspecting an absorbent article constructed from multiple components. A filtered image is produced from the absorbent article. In the image of the absorbent article, a nonlinear first edge and a second edge are identified at a location where there is a course change in contrast. A center point and centerline of the absorbent article is calculated using the position of the first edge and the second edge. A skew of the absorbent article is calculated. These known locations are utilized to define at least one additional region of the image for further analysis. A third edge and fourth edge are identified at a location where there is a fine change in contrast. The skew of the third edge and the fourth edge within the defined region is calculated and compared to known parameters for the absorbent article.

Abstract: One embodiment of the present invention provides a system that controls access to personally identifiable information (PII) in a database system. During operation, the system receives a request from an application to perform a function which involves accessing information in the database system. In response to the request, the system identifies a purpose that the application has in making request to perform the function. Next, the system uses the purpose to identify a set of attributes in the database system, which are associated with the purpose. The system then determines if any of the identified attributes contain PII. If so, the system enforces access controls while accessing the identified attributes containing PII.

Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form.

Abstract: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.

Abstract: A method and apparatus for arbitrating access to a memory, which has a plurality of banks. The method includes arbitrating with a plurality of processors. Each processor is associated with one of a plurality of data ports and has a plurality of arbitration cycles, including a current cycle and a most recent cycle preceding the current cycle. Each processor receives memory access requests from all of the data ports, wherein each memory access request is associated with one of the memory banks. Each processor selectively grants the data port associated with that processor access to the memory for the current cycle based on the banks associated with the memory access requests of each data port, the data port that was granted access to the memory during the preceding cycle, and the memory bank that was accessed during the preceding cycle.